The choice of either quetiapine or aripiprazole as augmentation treatment in a European naturalistic sample of patients with major depressive disorder

L Bartova, G Fugger, M Dold, A Kautzky… - International Journal …, 2022 - academic.oup.com
Background Augmentation with second-generation antipsychotics (SGAs) represents an
evidence-based psychopharmacotherapeutic strategy recommended in case of insufficient …
被引用次数：2 相关文章

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.

L Bartova, G Fugger, M Dold, A Kautzky… - The International …, 2022 - europepmc.org
Background Augmentation with second-generation antipsychotics (SGAs) represents an
evidence-based psychopharmacotherapeutic strategy recommended in case of insufficient …

[引用][C] The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder

L Bartova, G Fugger, M Dold, A Kautzky… - The international …, 2022 - difusion.ulb.ac.be
[PDF] oup.com

[PDF][PDF] The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder

L Bartova, G Fugger, M Dold, A Kautzky… - International Journal …, 2022 - academic.oup.com
Background Augmentation with second-generation antipsychotics (SGAs) represents an
evidence-based psychopharmacotherapeutic strategy recommended in case of insufficient …
[HTML] nih.gov

[HTML][HTML] The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder

L Bartova, G Fugger, M Dold, A Kautzky… - International Journal …, 2022 - ncbi.nlm.nih.gov
Background Augmentation with second-generation antipsychotics (SGAs) represents an
evidence-based psychopharmacotherapeutic strategy recommended in case of insufficient …

Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.

L Bartova, G Fugger, M Dold… - International …, 2022 - search.ebscohost.com
Background Augmentation with second-generation antipsychotics (SGAs) represents an
evidence-based psychopharmacotherapeutic strategy recommended in case of insufficient …

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder

L Bartova, G Fugger, M Dold, A Kautzky… - INTERNATIONAL …, 2022 - cris.unibo.it
Background Augmentation with second-generation antipsychotics (SGAs) represents an
evidence-based psychopharmacotherapeutic strategy recommended in case of insufficient …
[PDF] ulb.ac.be

[PDF][PDF] The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder

L Bartova, G Fugger, M Dold, A Kautzky… - International Journal of …, 2022 - dipot.ulb.ac.be
Background: Augmentation with second-generation antipsychotics (SGAs) represents an
evidence-based psychopharmacotherapeutic strategy recommended in case of insufficient …

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder

L Bartova, G Fugger, M Dold… - The international …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Augmentation with second-generation antipsychotics (SGAs) represents an
evidence-based psychopharmacotherapeutic strategy recommended in case of insufficient …